Abstract
The use of agents capable of impairing RTK function is gaining prominence for their effectiveness against the tumorigenic program driven by oncogenic RTK activity in a wide range of cancer cells. Having this valuable resource in hand for molecularly targeted anticancer therapies, it is mandatory to understand how to use these agents properly for combined treatments in order to maximize clinical efficacy. The remarkable plasticity and adaptation of cancer cells should also be taken into account, since this leads to the acquisition of “resistance” during treatment. By revisiting mechanisms of drug resistance found in cancer cells and by intercalating new emerging concepts on RTK signaling coming from cancer genome studies, this review discusses strategies aimed to enhance the effectiveness of RTK blocking agents and overcome resistance to treatment.
Keywords: RTK-addiction, oncogenic RTKs, RTK anticancer agents, mechanism of drug action, resistance mechanisms, cell plasticity.
Current Medicinal Chemistry
Title:Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Volume: 21 Issue: 14
Author(s): Flavio Maina
Affiliation:
Keywords: RTK-addiction, oncogenic RTKs, RTK anticancer agents, mechanism of drug action, resistance mechanisms, cell plasticity.
Abstract: The use of agents capable of impairing RTK function is gaining prominence for their effectiveness against the tumorigenic program driven by oncogenic RTK activity in a wide range of cancer cells. Having this valuable resource in hand for molecularly targeted anticancer therapies, it is mandatory to understand how to use these agents properly for combined treatments in order to maximize clinical efficacy. The remarkable plasticity and adaptation of cancer cells should also be taken into account, since this leads to the acquisition of “resistance” during treatment. By revisiting mechanisms of drug resistance found in cancer cells and by intercalating new emerging concepts on RTK signaling coming from cancer genome studies, this review discusses strategies aimed to enhance the effectiveness of RTK blocking agents and overcome resistance to treatment.
Export Options
About this article
Cite this article as:
Maina Flavio, Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells, Current Medicinal Chemistry 2014; 21 (14) . https://dx.doi.org/10.2174/09298673113209990222
DOI https://dx.doi.org/10.2174/09298673113209990222 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Pharmacological Modulation of Genome and Proteome Alterations in Mice Treated with the Endocrine Disruptor Bisphenol A
Current Cancer Drug Targets Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer
Neuroscience and Biomedical Engineering (Discontinued) The PYRIN Domain in Signal Transduction
Current Protein & Peptide Science 5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study
Medicinal Chemistry Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Polyphenols Counteract Tumor Cell Chemoresistance Conferred by Multidrug Resistance Proteins
Anti-Cancer Agents in Medicinal Chemistry The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry